Telegram-Icon YouTube-Icon Instagram-Icon

For Market’s Latest Update Join Us on Telegram

Arrow-Icon-in-Right-Direction

Loading IST Time...
8 Dec
Open Date Open
10 Dec
Close Date Close
11 Dec
Allotment Date Allotment
15 Dec
Listing Date Listing
[upstox_stock_summary instrument_key=”NSE_EQ|INE02ZQ01018″]

IPO GMP

IPO is a Mainboard IPO, the company will raise up to via this IPO. The IPO comprises a fresh issue of , and an offer for sale (OFS) of shares (amount) .

IPO will open for subscription on and close on . Basis of Allotment will be decided on , initiation of refund will begin on and finally IPO will be listed on at . is the book running lead manager and is the registrar of the IPO.

Total shares offered by IPO is . Out of which is reserved for retail, is reserved for HNI (NII), is reserved for QIB.

IPO Price Band and Market Lot

has set a price band of and lot size is of . Retail investors can bid for a minimum of lots ( shares), requiring minimum investment of , and maximun upto lots ( shares), requiring maximum investment of . Small HNI investors can bid for a minimum of lots ( shares), requiring an investment of , small hni (shni) investors can bid for a maximum of lots ( shares), requiring an investment of and big hni (bHNI) investors can bid for a minimum of Lots ( shares), requiring an investment of . Calculated at the cut-off price (the upper end of the price band).

IPO Subscription Status Today (Live)

Loading Latest IPO Data...

IPO GMP (Grey Market Premium) Today (Live)

Visit us daily to get the latest update on IPO GMP. IPO GMP started, and here you can get the latest update of IPO GMP.

IPO GMP today or grey market premium, and the Latest GMP Data pattern is available here.

  • Price Band of IPO is .
  • Current GMP (Grey Market Premium) for IPO is:
  • It is a premium for the IPO cut-off price .
  • As per IPO Taday’s GMP Data, the estimated listing price of IPO shares can be:
  • Estimated listing price calculated as IPO cutoff price or allotment price: + IPO current GMP: .
  • Corona Remedies IPO GMP
    DateGMP
    (₹)
    Listing Price
    (₹-Estimated)
    Today308
    9 December 2025255
    8 December 2025288
    7 December 2025325
    6 December 2025325
    5 December 2025365
    4 December 2025365
    3 December 2025300
    Corona Remedies
    Annual Performance (31 Mar 2025 vs 31 Mar 24)
    Corona Remedies's Assets increased by 12%, Revenue increased by 17.8%, Profit After Tax increased by 65.1%, EBITDA increased by 52.6%, Net Worth increased by 26.2%, Total Borrowing dropped by 53.3%, Reserves & Surplus increased by 30% compared to the previous financial year.
    Assets
    ▲ 12% (99.28)
    Revenue
    ▲ 17.8% (181.42)
    Profit After Tax
    ▲ 65.1% (58.93)
    EBITDA
    ▲ 52.6% (84.72)
    Net Worth
    ▲ 26.2% (125.93)
    Total Borrowing
    ▼ 53.3% (-71.44)
    Reserves & Surplus
    ▲ 30% (125.93)

    Previous Financial Year Growth (31 Mar 24 vs 31 Mar 23)
    Comparing 31 Mar 24 with 31 Mar 23, Assets increased by 39.6%, Revenue increased by 14.6%, Profit After Tax increased by 6.6%, EBITDA increased by 19.4%, Net Worth increased by 17.6%, Total Borrowing increased by 5657.1%, Reserves & Surplus increased by 20.7%.
    Assets (Prev Yr)
    ▲ 39.6% (235.56)
    Revenue (Prev Yr)
    ▲ 14.6% (129.83)
    Profit After Tax (Prev Yr)
    ▲ 6.6% (5.57)
    EBITDA (Prev Yr)
    ▲ 19.4% (26.16)
    Net Worth (Prev Yr)
    ▲ 17.6% (71.89)
    Total Borrowing (Prev Yr)
    ▲ 5657.1% (131.81)
    Reserves & Surplus (Prev Yr)
    ▲ 20.7% (71.89)

    2-Year Performance Change (31 Mar 23 To 31 Mar 2025)
    Between 31 Mar 2025 and 31 Mar 23, Assets increased by 56.3%, Revenue increased by 34.9%, Profit After Tax increased by 75.9%, EBITDA increased by 82.1%, Net Worth increased by 48.4%, Total Borrowing increased by 2591%, Reserves & Surplus increased by 56.9%.
    Assets (2-Yr Change)
    ▲ 56.3% (334.84)
    Revenue (2-Yr Change)
    ▲ 34.9% (311.25)
    Profit After Tax (2-Yr Change)
    ▲ 75.9% (64.5)
    EBITDA (2-Yr Change)
    ▲ 82.1% (110.88)
    Net Worth (2-Yr Change)
    ▲ 48.4% (197.82)
    Total Borrowing (2-Yr Change)
    ▲ 2591% (60.37)
    Reserves & Surplus (2-Yr Change)
    ▲ 56.9% (197.82)
      30 Jun 25 in crore 31 Mar 2025 in crore 31 Mar 24 in crore 31 Mar 23 in crore
    Assets 1,012.38 929.86 830.58 595.02
    Revenue 348.56 1,202.35 1,020.93 891.1
    Profit After Tax 46.2 149.43 90.5 84.93
    EBITDA 71.8 245.91 161.19 135.03
    Net Worth 607.02 606.34 480.41 408.52
    Total Borrowing 106.65 62.7 134.14 2.33
    Reserves & Surplus 545.86 545.18 419.25 347.36
    IPO Time Table (Tentative)
    IPO Open Date
    IPO Close Date
    Basis of Allotment Date
    Initiation of Refunds
    Credit of Share to Demat Account
    IPO Listing Date
    IPO Cut-off time (UPI mandate confirmation)
    IPO Reservation
    Retail Quota
    NII Quota
    QIB Quota
    Total
    IPO Price
    Face Value
    Price Band
    Lot Size
    IPO Issue Type

    About (Company Overview)

    Corona Remedies Limited founded in 2004 and headquartered in Ahmedabad, Gujarat, is an India focused branded pharmaceutical formulations company specializing in chronic and sub chronic therapies such as women’s healthcare, cardiology, diabetology, pain management, and urology. The company develops, manufactures, and markets a wide range of prescription medicines through a strong domestic distribution network covering urban and semi urban markets.

    The company operates multiple manufacturing facilities in India, including units in Gujarat and Himachal Pradesh, and these plants hold key quality certifications such as EU GMP and WHO GMP.

    The company ranks among the top Indian pharmaceutical players by domestic branded formulations and has positioned itself strongly in chronic lifestyle segments, which provide recurring long term demand. Its financial profile is characterized by healthy profitability, strong return ratios, and low leverage, reflecting a relatively conservative balance sheet and efficient capital use.

     

    IPO Frequently Asked Questions

    The latest Grey Market Premium (GMP) of IPO is .

    It is a premium to the IPO cut-off price . GMP gives a rough estimate of the premium at which the stock might list. It’s not guaranteed but often aligns with market sentiment.

    As per latest GMP data, the expected return for IPO can be .

    Expected listing listing price for share can be .

    According to latest GMP data pattern expected listing price and profit per share for IPO can be . Expected listing price is calculated by adding the GMP to the IPO issue price. Estimated listing price = IPO issue price + current GMP. This value changes as the GMP fluctuates.

    GMP is an unofficial indicator and can be manipulated. It should never be the sole reason to apply. Always consider fundamentals and your risk tolerance. Subscription demand, financial performance, market sentiment, peer valuation, and overall liquidity can impact the GMP trend.

     

    Disclaimer:

    • Grey market premium (GMP) indicates investors are willing to pay more than the issue price.
    • A negative GMP suggests that the IPO’s share is likely to be listed on the stock exchange at a discount, and a positive Grey Market Premium suggests that the IPO’s share is likely to be listed on the stock exchange at a profit.
    • Do not subscribe for IPO by just seeing the premium Price, It can change anytime
    • We do not trade/deal or buy/sell IPO forms in the grey market and GMP prices shown here are gathered from various sources.